JNMT
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gordon, L.
Right arrow Articles by Mah, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gordon, L.
Right arrow Articles by Mah, E.
Journal of Nuclear Medicine Technology Volume 30, Number 4, 2002 179-184
© 2002 by Society of Nuclear Medicine


IMAGING

Dual-Phase 99mTc-Sestamibi Imaging: Its Utility in Parathyroid Hyperplasia and Use of Immediate/Delayed Image Ratios to Improve Diagnosis of Hyperparathyroidism

Leonie Gordon, MD, William Burkhalter, MD and Eugene Mah, MSc

Department of Radiology, Medical University of South Carolina, Charleston, South Carolina

Objective: Dual-phase 99mTc-sestamibi (methoxyisobutylisonitrile [MIBI]) imaging is the technique of choice for hyperparathyroidism (HPT), especially for localizing parathyroid adenomas. Prior studies have shown its utility for detecting hyperplasia is equivocal, but we believe this is not true. We attempted to quantitate the region-of-interest counts per pixel between immediate images and delayed images (I/D ratio) and use this ratio to distinguish normal parathyroid versus hyperplasia versus adenoma.

Method: Anterior pinhole and upper thorax images with a low-energy, high-resolution collimator at 20 min and 2 h after 99mTc-MIBI injection were obtained on 54 subjects. The results were analyzed retrospectively as hyperplasia, adenoma, or normal parathyroid by the persistence of activity in 2 or more foci, a solitary focus, or no activity on the delayed images. These interpretations were compared with pathology when available. I/D ratios were computed for all scans, and mean ratios were calculated for each type of pathology (normal parathyroid, hyperplasia, and adenoma). The resulting ratios were analyzed with a t test to determine significant differences between the ratios.

Results: Sensitivity and specificity were 96% and 88%, respectively, for parathyroid hyperplasia. Mean I/D ratios were 2.26 ± 0.68, 2.80 ± 0.95, and 3.10 ± 0.77 for subjects with hyperplasia, adenoma, and normal parathyroid, respectively (hyperplasia vs. normal, P = 0.020; adenoma vs. normal, P = 0.381; hyperplasia vs. adenoma, P = 0.033).

Conclusion: Dual-phase 99mTc-MIBI imaging is more sensitive and specific for parathyroid hyperplasia than reported previously, supporting its use to localize hyperplastic glands preoperatively and to help guide resection. A thyroid ratio between immediate and delayed images will aid in distinguishing hyperplasia from normal parathyroid in uncertain cases.

Key Words: hyperparathyroidism; 99mTc-sestamibi; dual-phase parathyroid imaging




This article has been cited by other articles:


Home page
J. Nucl. Med. Technol.Home page
N. Hara, T. Takayama, M. Onoguchi, N. Obane, T. Miyati, T. Yoshioka, K. Sakaguchi, and M. Honda
Subtraction SPECT for Parathyroid Scintigraphy Based on Maximization of Mutual Information
J. Nucl. Med. Technol., June 1, 2007; 35(2): 84 - 90.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE JOURNAL OF NUCLEAR MEDICINE JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY
Copyright © 2002 by the Society of Nuclear Medicine Technologist Section.